Artimplant takes charge of its ATR products

Artimplant has entered into an agreement with its licensee, Biomet Sports Medicine, to assume total responsibility for sales of Artelon Tissue Reinforcement (ATR) products. Biomet has held the licence rights for Artimplant's ATR products since 2005. During 2007, the agreement was renegotiated from exclusive to non-exclusive for the US market. In conjunction with this, Artimplant began prospecting the market independently with the aim of increasing sales of ATR products more quickly.

The decision by Artimplant to terminate the licence agreement with Biomet is part of a new strategy of focusing exclusively on its own organisation and own sales. Another licence agreement, governing Artimplant's spacer products, was terminated at the end of 2011, and consequently Artimplant now has full responsibility for the sale of all its products on all markets.

This article is tagged to:
Sector: Medical Devices
Geography: Sweden

Access all of our latest analysis, data and forecasts - request a trial